CD19 and congenital rubella syndrome: A previous study reported that a higher rate of patients with DLBCL treated with CD28 costimulatory domain anti‐CD19 CAR‐T cells had CRS than those treated with 4‐1BB costimulation anti‐CD19 CAR‐T cells.56